DUBLIN, August 9, 2013 /PRNewswire/ --

Research and Markets (http://www.researchandmarkets.com/research/ppq2qd/global_lung) has announced the addition of the "Global Lung Cancer Therapeutics Market 2012-2016" report to their offering.

     (Logo: http://photos.prnewswire.com/prnh/20130307/600769 )

Global Lung Cancer Therapeutics Market To Grow At A CAGR Of 13.26 Percent Over The Period 2012-2016

The Global Lung Cancer Therapeutics Market 2012-2016 report has been prepared based on an in-depth analysis of the market with inputs from industry experts.

Commenting on the report, an analyst from the healthcare team said: "There has been an increase in medical tourism in the APAC region. Patients from all around world are visiting countries such as China and India for treatments. The healthcare facilities in the APAC region are improving, with excellent healthcare providers providing better treatment for diseases such as cancer or any other treatment at a low cost. Thus, the increase in the number of patients coming to China and India for cancer treatment is a growing trend, which is encouraging the healthcare organizations to opt for more lung cancer therapeutic drugs."

According to the report, one of the major growth factors driving the Global Lung Cancer Therapeutics market is the increase in the prevalence of cancer patients worldwide. Therapeutic drugs are among the remedies for cancer, and hence healthcare organizations are opting for lung cancer therapeutic drugs for treatments. Moreover, most of the vendors are focusing significantly on the US market, which is expected to witness a faster growth rate than the global CAGR during the period 2012-2016.


Key Topics Covered

1. Executive Summary
2. Introduction
3. Market Coverage
4. Market Landscape
5. Geographical Segmentation
6. Key Leading Countries
7. Rate of Incidence and Prevalence
8. Vendor Landscape
9. Buying Criteria
10. Market Growth Drivers
11. Drivers and their Impact
12. Market Challenges
13. Impact of Drivers and Challenges
14. Market Trends
15. Key Vendor Analysis
16. Other Reports in this Series 

Companies Mentioned

- ARIAD Pharmaceuticals
- Ambit Biosciences
- AstraZeneca
- Biogen Idec
- Bristol-Myers Squibb
- Cephalon
- Clavis Pharma
- ERYtech Pharma
- Eisai
- Eli Lilly
- Genmab
- Genzyme
- GlaxoSmithKline
- Hoffmann-La Roche
- Novartis
- Pfizer
- Sunesis Pharmaceuticals
- Talon Therapeutics
- Teva Pharmaceutical Industries

For more information visit http://www.researchandmarkets.com/research/ppq2qd/global_lung

About Research and Markets

Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Research and Markets
Laura Wood, Senior Manager.
press@researchandmarkets.com
U.S. Fax: +1-646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Lung Cancer

SOURCE Research and Markets